Regeneron’s ultra-rare-disease drug won U.S. regulatory approval after a three-decade effort.
FDA approves Ultragenyx gene therapy and Regeneron secures ultra-rare disease approval, underscoring regulatory momentum for gene therapies and mRNA platforms, per The Readout.